2026-06-04
40 分钟Welcome to Huberman Lab Essentials, where we revisit past episodes for the most potent
and actionable science-based tools for mental health, physical health, and performance.
I'm Andrew Huberman, and I'm a professor of neurobiology and ophthalmology at Stanford School of Medicine.
And now for my discussion with Dr. Nolan Williams.
Thanks for joining today.
I'm really excited to have this conversation.
I have a lot of questions about different compounds, psychedelics in particular.
But before we get into that discussion, I want to ask you about depression, broadly speaking.
I heard you say in a wonderful talk that you gave that depression is perhaps the most debilitating condition worldwide.
Yet in contrast to other medical conditions like cancer,
we actually have a fairly limited number of tools to approach depression.
And yet the number of tools and the potency of those tools is growing.
Depression is the most disabling condition worldwide.
What's interesting about depression is it's both a risk factor for other illnesses
and it makes other medical and psychiatric illnesses worse.
So recently, the American Heart Association added depression
as the fourth major risk factor for coronary artery disease.
So alongside the risk factors that we know, hypertension, high blood pressure, hyperlipidemia, high cholesterol.
And diabetes, high blood sugar, those three have been on the list for a long time,
and depression ends up being added to the list as the fourth one.